Biosimilars LatAm – Colombia 2023
The forum was created to serve as a platform for communication and collaboration between INVIMA, the national regulatory agency, and pharmaceutical manufacturers in the region.
The forum aims to address pressing industry concerns, provide feedback, and identify potential next steps for the industry. The presence of international experts will also provide an opportunity to share best practices in communication and building trust between regulatory agencies and the companies they regulate, with a specific focus on the communication between the reference agency ANVISA and its regulated companies.
The program is designed to enhance the understanding of the local capacity for research and development of biosimilars, as well as to explore the potential for public-private partnerships between government entities and pharmaceutical companies to produce these treatments.
The primary focus is on efforts by the National Government and private industries to identify and establish mutually beneficial alliances for technology transfer and the production of biosimilars, vaccines, and other medical technologies within Colombia.
This trend towards expansion, development, and investment in the biosimilars market holds great promise for patients as it can lead to greater access to therapeutic options and help to address disparities in healthcare access in the region.
Similar successful examples can be seen in neighboring countries like Brazil and Mexico, where biosimilars have been implemented to facilitate the production of Covid vaccines through Partnerships for Productive Development (PPD). The forum aims to replicate these successes within the region of Colombia.
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board
Carolina Wiesner Ceballos
General Director
Carlos Francisco Fernández
President
Ignacio Mejia Calvo
Services Manager
Victor Romero Vieco
Business Unit Manager Access and Specialties
Johanna García Cortes
Regulatory Adviser
Sandra Garcia
Service Manager
Alfredo Moreno
CCO
Luz Dary Riano
CEO
Aurelio Enrique Mejía Mejía
General Manager
Andrea Bedoya López
Leader of Biotechnological Medicines Group
Clara Rodriguez Sanchez
Executive Director
Alejandro Gómez López
Secretary of Health of Bogota
Nicole Lazo Bolaños
Specialist in the Sanitary Evaluation of Biological Products
Edgar Javier Arias Ramirez
Production Director
Juan David Moncaleano
First Secretary
Anderson Montai
Manager, Specialist in Health Regulation and Surveillance
Juan Carlos Gonzalez Vergara
Vice-President for Competitiveness
Stephan Jarpa Cuadra
MinAgri Chile, Former Advisor Cabinet Minister
Guillermo Pardo
VP Operations & COO
Mauricio Rubio
Country Manager Colombia
Claudia Vaca
Founder and Head
Program at a Glance
Regulatory Updates (INVIMA)
Get first hand information on the current regulatory changes and updates in Colombia.
What Are the Country's Resources to Face the Possible Local Production of Biosimilars?
To acknowledge the regulatory, professional, academic and technological resources to face biosimilars development and production in Colombia.
Biosimilar Initiatives, and How Close Is Local Production?
What are the actual initiatives that promise to be the first development of biosimilars in the country.
Round table. INVIMA & Local Producers.
Discussion of local industry needs for INVIMA recognition and feedback, and possible next steps.
Health Authorities Success in LatAm (ANVISA, DIGEMID)
Efforts made to build trust with the regulated companies in the biosimilars market.
Full Programme in the PDF Agenda
Download Agenda